• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Cessation of aspirin in older adults not associated with adverse health effects

byDavid XiangandHarsh Shah
March 30, 2022
in Chronic Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Aspirin cessation in older adults led to increased cardiovascular disease events, though not statistically significant.

2. Aspiring cessation in older adults was not significantly associated with any change in mortality.

Evidence Rating Level: 1 (Excellent)

Study Rundown: A prior randomized, double-blind placebo-controlled primary prevention trial of aspirin demonstrated that aspirin had no benefit for disability-free survival, prevention of cardiovascular disease events, or prevention of incident cancer. These findings were interpreted as being relevant only to aspirin initiation, but there is a gap in knowledge as to understanding the risks and benefits of aspirin cessation among older adults. This study found that aspirin cessation was not significantly associated with any changes in disability-free survival or other clinical outcomes such as dementia, or persistent physical disability, and though statistically insignificant, aspirin cessation did increase cardiovascular disease events. This study was limited by factors such as a gap in continuous exposure for those randomly assigned to aspirin, as well as the study group having reduced statistical power and likely self-selection for tolerance. Nevertheless, these study’s findings are significant, as they demonstrate that aspirin cessation, especially in patients with a large medication burden or clinical history, should be conducted with due caution as the cessation of aspirin might lead to adverse health outcomes among older adults.

Click to read the study in AIM

Relevant Reading: Does Stopping Aspirin Differ Fundamentally From Not Starting Aspirin in the Primary Prevention of Cardiovascular Disease Among Older Adults?

In-Depth [randomized subgroup analysis]: This subgroup analysis utilized the Aspirin in Reducing Events in the Elderly (ASPREE) randomized trial. Patients who reported taking aspirin 2 or more days per week at enrollment were eligible for the study. Patients who were younger than 70 years and did not report taking aspirin 2 or more days per week were excluded from the study. The primary outcome measured was a composite of all-cause mortality, incident dementia, or persistent physical disability. Outcomes in the primary analysis were assessed via Cox proportional hazards regression with additional subgroup analyses based on age, race, and years of pretrial aspirin exposure. Based on the analysis, evidence of increased risk for the primary outcome for aspirin cessation was statistically insignificant. Overall, 13.8% of participants in the aspirin cessation group and 11.1% in the continuation group experience the primary endpoint, with a hazard ratio for cessation versus continuation of 1.28 (95% confidence interval [CI], 0.98 to 1.68). Additionally, although not statistically significant, aspirin cessation increased cardiovascular disease events among those who had reported taking aspirin for 5 years or longer. Age also had no impact on the effect of aspirin cessation. In conclusion, this study demonstrated that aspirin cessation was not statistically associated with any changes in all-cause mortality, dementia, or physical disability, though the reduced statistical power of this study limits the definitive conclusions that this study can draw. Nevertheless, these results suggest that prior to aspirin cessation, careful consideration of the patient’s medication and the clinical burden should be conducted.

RELATED REPORTS

Increased risk of intracranial hemorrhage with aspirin and unfractionated heparin use for endovascular stroke treatment

Aspirin use was not effective at reducing mortality in patients hospitalized with COVID-19

#VisualAbstract: Bullous pemphigoid was associated with a five-fold increase in cardiovascular disease mortality

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: all-cause mortalityaspirincardiovascular disease eventsdisability-free survivalolder adults
Previous Post

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

Next Post

Prenatal exposure to antipsychotic medications not associated with increased risk of neurodevelopmental disorders in offspring

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Increased risk of intracranial hemorrhage with aspirin and unfractionated heparin use for endovascular stroke treatment

March 22, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Cardiology

Aspirin use was not effective at reducing mortality in patients hospitalized with COVID-19

January 25, 2022
#VisualAbstract: Bullous pemphigoid was associated with a five-fold increase in cardiovascular disease mortality
StudyGraphics

#VisualAbstract: Bullous pemphigoid was associated with a five-fold increase in cardiovascular disease mortality

January 7, 2022
#VisualAbstract: Higher proportions time spent in physical activity decreased all-cause mortality
StudyGraphics

#VisualAbstract: Higher proportions time spent in physical activity decreased all-cause mortality

December 1, 2021
Next Post
Publication of pneumonia antibiotic guidelines changed prescribing trends

Prenatal exposure to antipsychotic medications not associated with increased risk of neurodevelopmental disorders in offspring

Influenza vaccine not associated with increased risk of epilepsy in children

Single-dose Ad26.COV2.S reduces risk of COVID-related hospitalization and death in South African healthcare workers

#VisualAbstract: Cardiosphere-derived cell therapy slows disease progression in Duchenne muscular dystrophy

#VisualAbstract: Cardiosphere-derived cell therapy slows disease progression in Duchenne muscular dystrophy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.